SAWT BEIRUT INTERNATIONAL

| 21 June 2021, Monday | النسخة العربية

Gebara says no need to panic, subsidies will not be lifted on chronic disease medicines  

Rania Ghanem
A A A
Print

With the Central Bank’s reserves dwindling, it is only a matter of time before the government bids farewell to subsidies on wheat, fuel and mainly medicine.

This reality has raised citizens’ concerns and panics, and created a tiresome routine of visiting pharmacies, hunting for a pillbox that is, in many cases, as important as food and water.

No signs so far for lifting support

In fact, there is no reason for panicking so far, as Karim Gebara, President of the Lebanese Pharmaceutical Importers Association (LPIA)  told “Sawt Beirut International” that neither the government nor the Central Bank has notified importers of any decision for lifting subsidies on medicine so far.

Gebara added that the plan proposed by the specialized committee to develop a policy for rationing support suggested segmenting medicine into three categories. The first category includes medicines that do not require medical prescription to purchase it, the second category includes medicines that are for a periodic treatment, and the third category includes medicines for chronic and incurable diseases. Gebara said that subsidies will be lifted from the third category only. The prices of the first and second category medicines will be calculated according the exchange rate of 3,900 LBP, however, the plan was prepared when the dollar exchange rate on the black market was about 8,000 LBP, for this reason the approach may change after the Lebanese pound tumbled to 13,000 against dollar.

Significant increase in demand

As a result of the citizen’s panic over the lifting of subsidies, pharmaceutical importers saw a tangible increase in demand from pharmacies in 2020, estimated at 2 percent, compared to a 5 percent drop in 2019. Demand focused specifically on chronic diseases medicines. For example, the demand for diabetes medicines, in terms of the number of packs, increased by 16 percent in 2020, compared to the previous year, noting that it had decreased by 2 percent compared to 2018. Cardiovascular disease drugs  increased by 13 percent in the same period, compared to an increase of only 1 percent in 2019. As for neuropathy drugs, it increased by 11 percent, compared to an increase of only 2 percent in 2019.

Impact of lifting subsidies

Gebara said that lifting subsidies on pharmaceuticals will lead to a drop in medicine consumption, especially for medicines that are taken without medical prescription, such as cold and cough medicines, and others. Demand will concentrate on generics that are of lower prices, noting that 90 percent of medicines in Lebanon have an average price of 10,000 LBP. Gebara confirmed that lifting support will create a lot of hurdles for guarantors. He sounded alarm that this reality will intensify the entrance of counterfeited and ineffective drugs into the market.”

Gebara concluded that stocks of many pharmaceutical companies today are “barely enough to last for a month and a half, as a maximum. There is shortage of some medicines as well, especially that some containers are stuck in warehouses after the Central Bank issued a new mechanism that obliges importers to get its approval before importing any container to Lebanon.